erythema

By Targets:	Bacterial (1) Biochemical Assay Reagents (1) Caspase (2) COX (3) Isotope-Labeled Compounds (1) Platelet-activating Factor Receptor (PAFR) (1)
By Research Areas:	Infection (1) Inflammation/Immunology (5)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17361

Etofenamate	COX	Inflammation/Immunology
Etofenamate, a non-steroid anti-inflammatory agent (NSAID) and a non-selective COX inhibitor, possesses analgesic, anti-rheumatic, antipyretic and anti-inflammatory properties. Etofenamate is used in the research for osteoarthritis, arthritis and other inflammatory diseases .

HY-B1695

Methyl nicotinate Nicotinic acid methyl ester
Methyl nicotinate (Nicotinic acid methyl ester) is an orally active vasodilator. Methyl nicotinate has analgesic activity. Methyl nicotinate causes local skin erythema when applied topically to the skin. Methyl nicotinate is used as an active ingredient in over-the-counter topical preparations for the study of muscle and joint pain .

HY-B1138

Fenbufen CL-82204	COX Caspase	Inflammation/Immunology
Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC₅₀s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor .

HY-D1005A10

Poloxamer 184 (L64) PEG-PPG-PEG, 2900 (Averag)	Biochemical Assay Reagents Bacterial	Infection Inflammation/Immunology
Poloxamer 184 L64 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2900. Poloxamer 184 L64 exhibts short-term dermal toxicity characterized by slight erythema and intradermal inflammatory response. Poloxamer 184 L64 exhibits antimicrobial activity, that inihibits 60% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 184 L64 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .

HY-106837

Israpafant Y 24180	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC₅₀s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca ²⁺ influx and intracellular Ca ²⁺ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice .

HY-B1138S

Fenbufen-d9	Isotope-Labeled Compounds COX Caspase	Inflammation/Immunology
Fenbufen-d₉ (CL-82204-d9) is the deuterium labeled Fenbufen. Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor[1][2][3][4][5].

Cat. No.	Product Name

HY-L140

Withdrawn Drug Compound Library	198 compounds
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug. Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications. MCE has sorted out 198 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Withdrawn Drug Compound Library

198 compounds

Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.

Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.

MCE has sorted out 198 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Cat. No.	Product Name	Type

HY-D1005A10

Poloxamer 184 (L64) PEG-PPG-PEG, 2900 (Averag)	Co-solvents
Poloxamer 184 L64 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2900. Poloxamer 184 L64 exhibts short-term dermal toxicity characterized by slight erythema and intradermal inflammatory response. Poloxamer 184 L64 exhibits antimicrobial activity, that inihibits 60% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 184 L64 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .

Poloxamer 184 (L64)

PEG-PPG-PEG, 2900 (Averag)

Co-solvents

Poloxamer 184 L64 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2900. Poloxamer 184 L64 exhibts short-term dermal toxicity characterized by slight erythema and intradermal inflammatory response. Poloxamer 184 L64 exhibits antimicrobial activity, that inihibits 60% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 184 L64 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .

Cat. No.	Product Name	Chemical Structure

HY-B1138S

Fenbufen-d9
Fenbufen-d₉ (CL-82204-d9) is the deuterium labeled Fenbufen. Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor[1][2][3][4][5].

Fenbufen-d9

Fenbufen-d₉ (CL-82204-d9) is the deuterium labeled Fenbufen. Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor[1][2][3][4][5].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.